The Hindu Business Line : Teams up with GSK for drug development

Dr Reddy’s Laboratories Ltd has entered into a partnership with GlaxoSmithKline Plc (GSK) to develop and market select products in generics and differentiated formulations across emerging markets outside India.

As per the agreement, GSK has gained access to Hyderabad-based company’s diverse portfolio and future pipeline of more than 100 branded pharmaceuticals in therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.

“We are extremely pleased to combine forces with GSK, a global leader, to fully realise the potential of our strengths in technology, product development and manufacturing across a range of high growth emerging markets,” Mr G.V. Prasad, Vice-Chairman and Chief Executive Officer, Dr Reddy’s, said in a release.

The products would be manufactured by Dr Reddy’s and would be licensed and supplied to GSK in various emerging markets such as Africa, West Asia, Latin America and Asia Pacific, excluding India.

In certain markets, products would be co-marketed by both the companies.

While not disclosing the financial aspects of the deal, Dr Reddy’s said revenues would be reported by GSK and would be shared with Dr. Reddy’s.

“This new alliance would combine Dr Reddy’s portfolio of high quality branded pharmaceuticals together with GSK’s extensive sales and marketing capabilities. This is another significant step forward in our strategy to grow and diversify GSK’s business in emerging markets,” Mr Abbas Hussain, President, Emerging Markets, GlaxoSmithKline said.

The growth in both population and economic prosperity was leading to increased demand for branded pharmaceuticals, he added.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Australia’s nod for Aurobindo drug

Ansal Properties QIPs to raise Rs 1,500 cr

RIL-RNRL dispute: Await more twists in the tale

RIL-RNRL case: Ministry awaits Court order

Court directs Reliance to sell gas to RNRL at $2.34

Balmer Lawrie dividend

Dr Reddy’s Laboratories to hire 1,300 this year

Suzlon says it is considering options for its stake in Hansen Transmissions

GAIL to invest Rs 5,558 cr in 2009-10

British company opens facility

Teams up with GSK for drug development

Tata Motors, Bank of India tie up

TVS to ride on new bikes towards double-digit growth

Swine flu cases in India spike to 30

SAIL gets new Director of Projects